Tuesday, March 14, 2023
Pfizer and Seagen announced that they have entered into a definitive merger agreement under which Pfizer will acquire Seagen for US$229 in cash per Seagen share for a total enterprise value of US$43 billion.
Together, Pfizer and Seagen will accelerate the next generation of cancer breakthroughs and bring new solutions to patients by combining the power of Seagen’s antibody-drug conjugate (ADC) technology with the scale and strength of Pfizer’s capabilities and expertise.
The addition of Seagen’s world-leading ADC technology makes its position at the forefront of innovative cancer care, and strongly complements the existing portfolio across both solid tumours and haematologic malignancies.
The combination of teams, and respective areas of strength and global footprints will allow to realise Seagen’s potential and advance even more potential breakthroughs to patients with cancer.
